GenVec will stop enrolling patients in a Phase II trial testing the company's drug for treating severe coronary artery disease. The company will focus on its cancer-drug development instead, it announced.
Patients already enrolled in the Phase II study of the heart drug, called BioBypass, will complete follow-up and data will be collected and analyzed in accordance with the research agreement between GenVec and its collaborator, Cordis.
